Simultaneous detection of multiple gene mutations in non-small-cell lung cancer

Your details:

Email *

* Required

First Name *

* Required

Last Name *

* Required

Job Function *

* Required

Company/ Organization *

* Required

Country *

* Required

State/Province *

* Required

City

* Required

ZIP Code

* Required

Please confirm the type of organization do you work for? *

* Required

Are you currently doing multiplexing assays? *

* Required

What technology are you using for multiplexing assays? (multiple choices) *

a) Digital PCR b) qPCR c) NGS d) Other technology * Required

Yes, please email me from time to time about Springer Nature programs, products or services (tick to consent). You can withdraw consent at any time by clicking on the unsubscribe link at the bottom of these emails. * Required

Yes, please contact me from time to time about the sponsor’s respective programs, products or services (tick to consent). You can withdraw consent at any time by contacting the sponsor. * Required

By registering here, you agree that we can contact you to provide you with information about this webcast and your registration details will be seen by Springer Nature and the sponsor. We will not otherwise disclose your personal data to anyone else unless we have your permission as detailed in our Privacy Policy. Terms and conditions can be viewed here. *

I Agree * Required

Our registration process uses cookies, by submitting this registration form you agree to our cookie policy.

(*) denotes required form field(s)

Overview

If you’ve already registered, please click here to log in tothe webcast

Mutations in the epidermal growth factor receptor gene (EGFR) and the known Kirsten rat sarcoma viral oncogene (KRAS) are significant drivers in the development of non-small-cell lung cancer (NSCLC). Treatment is typically guided by which mutations are present, and there are several possible mutations that can arise during treatment, so detecting them quickly and reliably is key to helping the patient.

With NSCLC, biopsied patient samples tend to be very small, which can hamper many conventional genetic tests. Thus the ideal test in NSCLC is one that can work with minimal inputs, and test for several mutations at the same time.

This webcast will present a new liquid biopsy test using multiplexing assays that contained mutant variants. The QX ONE Droplet Digital PCR (ddPCR) System allows for automated operation and advanced multiplexing to detect mutations in EGFR and KRAS using as little as 5 ng of cell-free DNA extracted from plasma.

The speaker will address:

What are the key benefits to having a high-throughput, multiplexing ddPCR system?
Are the results the same between standard duplex reactions and multiplexed reactions?
What is the greatest number of samples that can be processed to results overnight on the QX200 vs the QX ONE?

This webcast has been produced on behalf of the sponsor who retains sole responsibility for content. About this content.

Presenters

Hestia Mellert, Ph.D.

Sr. Director, Development
Biodesix, Inc.
View Biography

Moderator: Sarah Hiddleston

Science Journalist
Nature Research Custom Media
View Biography

WorkCast Online Event & Presentation Platform